Expert Opinions September 5, 2012

Are pharmacological approaches to increasing HDL cholesterol clinically relevant in reducing the risk of atherogenic dyslipidemia and abdominal obesity?

Ronald Krauss, MD, Children's Hospital Oakland Research Institute, Atherosclerosis Research, Oakland, CA, USA